The chart below shows how ASND performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ASND sees a -1.30% change in stock price 10 days leading up to the earnings, and a +5.58% change 10 days following the report. On the earnings day itself, the stock moves by +0.50%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Skytrofa Revenue and Market Share: Skytrofa revenue reached approximately EUR 200 million in 2024, capturing a 6.5% market share of the total growth hormone market in the U.S. and around 45% of the long-acting growth hormone market.
Strong Revenue Performance: YorvaPath generated EUR 13.6 million in revenue for Q4 2024, contributing to a total of EUR 28.7 million for the full year, with strong early demand and positive reimbursement progress in the U.S.
Cash Position and Investment Potential: Ascendis Pharma ended 2024 with cash and cash equivalents totaling EUR 665 million, bolstered by a $100 million upfront payment from Novo Nordisk, positioning the company for continued investment in growth and development.
Skytrofa Volume Surge: Skytrofa volume increased by 84% in 2024, with premium net pricing three times that of daily growth hormone, indicating strong market acceptance and potential for future growth.
TransCon CMP Clinical Trial Success: TransCon CMP demonstrated significant improvements in linear growth and body proportionality in clinical trials, supporting its potential as a best-in-class treatment for achondroplasia, with NDA submission planned for Q1 2025.
Negative
Revenue Decline Despite Volume Increase: Skytrofa revenue decreased to EUR 58.5 million in Q4 2024 from EUR 64.2 million in Q4 2023, indicating a decline in financial performance despite a 37% increase in volume.
Operating Expenses Increase: Total operating expenses for Q4 2024 rose to EUR 159.5 million, a 3% increase from EUR 154.9 million in Q4 2023, reflecting rising costs despite revenue challenges.
R&D Cost Reduction Insights: R&D costs decreased by 13% in Q4 2024, but this was primarily due to lower external development costs, suggesting potential setbacks in product development initiatives.
Net Finance Expenses Analysis: Net finance expenses for the full year 2024 were EUR 74.4 million, primarily driven by non-cash items, indicating financial strain despite a strong cash position.
Treasury Shares Preservation: The company expects to use approximately $25 million in Q1 2025 to preserve around 200,000 ADS held as treasury shares, indicating potential liquidity concerns.
Earnings call transcript: Ascendis Pharma Q4 2024 sees revenue rise
ASND.O
0.44%